According to Fortune Business Insights, the global non-steroidal anti-inflammatory drugs (NSAIDs) market was valued at USD 15.58 billion in 2019 and is projected to reach USD 32.33 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period. North America dominated the market in 2019, holding a share of 44.03%.
